Journal of Gastroenterology

, Volume 44, Issue 5, pp 365–371

Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review

  • Masanori Ito
  • Shunsuke Takata
  • Masana Tatsugami
  • Yoshihiro Wada
  • Shinobu Imagawa
  • Yoshiaki Matsumoto
  • Akemi Takamura
  • Shosuke Kitamura
  • Taiji Matsuo
  • Shinji Tanaka
  • Ken Haruma
  • Kazuaki Chayama
Review

Abstract

Helicobacter pylori (H. pylori) infection plays an important role in gastric carcinogenesis. We conducted a systematic review concerning gastric cancer development after H. pylori eradication therapy. In total 15 papers matched our criteria, the results were reviewed. The H. pylori eradication therapy statistically diminished the prevalence of clinical gastric cancer by approximately one-third. The studies from Japan supported this conclusion; however, studies from overseas reported conflicting results. The differences in these conclusions lie in the diagnostic ability of endoscopic examination, since the clinical stage was quite different between these studies. Gastric cancer that developed after eradication revealed a mainly intestinal type histology and depressed-type appearance. The following are possible reasons for reduced gastric cancer: (1) eradication therapy inhibits the new occurrence of gastric cancer, (2) eradication regresses or inhibits the growth of gastric cancer, and (3) eradication interferes with the discovery of gastric cancer. Considering the biological nature of cancer cell proliferation, a sufficiently long-term follow-up may clarify the effect of eradication therapy on inhibition of the development (not discovery) of gastric cancer and reduction of gastric cancer-related mortality.

Keywords

H. pylori Eradication Gastritis Gastric cancer Systematic review 

References

  1. 1.
    Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004;(157):327–49.Google Scholar
  2. 2.
    Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, Matsuno Y, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet. 2008;40:730–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, Aung PP, et al. Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res. 2004;64:2397–405.PubMedCrossRefGoogle Scholar
  4. 4.
    Goodman KJ, Cockburn M. The role of epidemiology in understanding the health effects of Helicobacter pylori. Epidemiology. 2001;12:266–71.PubMedCrossRefGoogle Scholar
  5. 5.
    Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol. 2007;42:1–15.PubMedCrossRefGoogle Scholar
  6. 6.
    Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325:1132–6.PubMedGoogle Scholar
  7. 7.
    Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–31.PubMedGoogle Scholar
  8. 8.
    IARC Working Group. Schistosomes, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.Google Scholar
  9. 9.
    Correa P. Helicobacter pylori and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:238s–41s.PubMedGoogle Scholar
  10. 10.
    Kawaguchi H, Haruma K, Komoto K, Yoshihara M, Sumii K, Kajiyama G. Helicobacter pylori infection is the major risk factor for atrophic gastritis. Am J Gastroenterol. 1996;91:959–62.PubMedGoogle Scholar
  11. 11.
    Haruma K, Komoto K, Kawaguchi H, Okamoto S, Yoshihara M, Sumii K, et al. Pernicious anemia and Helicobacter pylori infection in Japan: evaluation in a country with a high prevalence of infection. Am J Gastroenterol. 1995;90:1107–10.PubMedGoogle Scholar
  12. 12.
    Ito M, Haruma K, Kaya S, Kamada T, Kim S, Sasaki A, et al. Role of anti-parietal cell antibody in Helicobacter pylori-associated atrophic gastritis: evaluation in a country of high prevalence of atrophic gastritis. Scand J Gastroenterol. 2002;37:287–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Komoto K, Haruma K, Kamada T, Tanaka S, Yoshihara M, Sumii K, et al. Helicobacter pylori infection and gastric neoplasia: correlations with histological gastritis and tumor histology. Am J Gastroenterol. 1998;93:1271–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Haruma K, Komoto K, Kamada T, Ito M, Kitadai Y, Yoshihara M, et al. Helicobacter pylori is a major risk factor for gastric carcinoma in young patients. Scand J Gastroenterol. 2000;35:255–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Hatakeyama M. Helicobacter pylori and gastric carcinogenesis, J Gastroenterol 2009 (in press).Google Scholar
  17. 17.
    Higashi H, Yokoyama K, Fujii Y, Ren S, Yuasa H, Saadat I, et al. Epiya motif is a membrane targeting signal of Helicobacter pylori CagA in mammalian cells. J Biol Chem. 2005;280:23130–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science. 2002;295:683–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Higashi H, Tsutsumi R, Fujita A, Yamazaki S, Asaka M, Azuma T, et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci USA. 2002;99:14428–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Kato S, Matsukura N, Tsukada K, Matsuda N, Mizoshita T, Tsukamoto T, et al. Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci. 2007;98:790–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187–94.PubMedCrossRefGoogle Scholar
  22. 22.
    Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut. 2004;53:1244–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005;54:1536–40.PubMedCrossRefGoogle Scholar
  24. 24.
    Zhou LY, Lin SR, Ding SG, Huang XB, Zhang L, Meng LM, et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chin J Dig Dis. 2005;6:114–5.PubMedCrossRefGoogle Scholar
  25. 25.
    You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98:974–83.PubMedCrossRefGoogle Scholar
  26. 26.
    Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997;6:639–42.PubMedGoogle Scholar
  27. 27.
    Kato M, Asaka M, Nakamura T, Azuma T, Tomita E, Kamoshida T, et al. Significance of Helicobacter pylori eradication on incidence of gastric cancer. Aliment Pharmacol Ther. 2006;24(suppl 4):203–6.Google Scholar
  28. 28.
    Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005;100:1037–42.PubMedCrossRefGoogle Scholar
  29. 29.
    Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007;42(suppl 17):21–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Takenaka R, Okada H, Kato J, Makidono C, Hori S, Kawahara Y, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther. 2007;25:805–12.PubMedGoogle Scholar
  31. 31.
    Ogura K, Hirata Y, Yanai A, Shibata W, Ohmae T, Mitsuno Y, et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol. 2008;42:279–83.PubMedGoogle Scholar
  32. 32.
    Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:350–2.CrossRefGoogle Scholar
  33. 33.
    Kokkola A, Sipponen P, Arkkila P, Danielson H, Puolakkainen P. Does the eradication of Helicobacter pylori delay the diagnosis of gastric cancer? Scand J Gastroenterol. 2008;43:1456–60.PubMedCrossRefGoogle Scholar
  34. 34.
    Kamada T, Hata J, Sugiu K, Kusunoki H, Ito M, Tanaka S, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther. 2005;21:1121–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Takata S, Ito M, Yoshihara M, Tanaka S, Imagawa S, Haruma K, et al. Host factors contributing to the discovery of gastric cancer after successful eradication therapy of Helicobacter pylori: preliminary report. J Gastroenterol Hepatol. 2007;22:571–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007;13:470–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Naito Y, Yoshikawa T. Molecular and cellular mechanisms involved in Helicobacter pylori-induced inflammation and oxidative stress. Free Radic Biol Med. 2002;33:323–36.PubMedCrossRefGoogle Scholar
  38. 38.
    Naito Y, Takagi T, Yoshikawa T. Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease. J Gastroenterol. 2007;42:787–98.PubMedCrossRefGoogle Scholar
  39. 39.
    Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Figueroa LS, Halperin D, et al. Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev. 2004;13:4–10.PubMedCrossRefGoogle Scholar
  40. 40.
    Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000;119:7–14.PubMedCrossRefGoogle Scholar
  41. 41.
    Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst. 2000;92:1881–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Haruma K, Mihara M, Okamoto E, Kusunoki H, Hananoki M, Tanaka S, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus. Evaluation of 24-h pH monitoring. Aliment Pharmacol Ther. 1999;13:155–62.PubMedCrossRefGoogle Scholar
  43. 43.
    Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, et al. Improvement of atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med. 2001;134:380–6.PubMedGoogle Scholar
  44. 44.
    Sugiyama T, Sakaki N, Kozawa H, Sato R, Fujioka T, Satoh K, et al. Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment. Aliment Pharmacol Ther. 2002;16(suppl 2):187–90.PubMedCrossRefGoogle Scholar
  45. 45.
    Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther. 2002;16:1449–56.PubMedCrossRefGoogle Scholar
  46. 46.
    Gotoda T, Saito D, Kondo H, Ono H, Oda I, Fujishiro M, et al. Endoscopic and histological reversibility of gastric adenoma after eradication of Helicobacter pylori. J Gastroenterol. 1999;34(Suppl 11):91–6.PubMedGoogle Scholar
  47. 47.
    Haruma K, Suzuki T, Tsuda T, Yoshihara M, Sumii K, Kajiyama G. Evaluation of tumor growth rate in patients with early gastric carcinoma of the elevated type. Gastrointest Radiol. 1991;16:289–92.PubMedCrossRefGoogle Scholar
  48. 48.
    Sasaki A, Kitadai Y, Ito M, Sumii M, Tanaka S, Yoshihara M, et al. Helicobacter pylori infection influences tumor growth of human gastric carcinomas. Scand J Gastroenterol. 2003;38:153–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Suzuki M, Suzuki H, Masaoka T, Tanaka S, Suzuki K, Ishii H. Helicobacter pylori eradication treatment modulates epithelial cell proliferation and tissue content of hepatocyte growth factor in the gastric mucosa. Aliment Pharmacol Ther. 2004;20(suppl 1):158–64.PubMedCrossRefGoogle Scholar
  50. 50.
    Naito Y, Ito M, Suzuki H, Watanabe T. Biomarkers in patients with gastric inflammation: a systematic review. Digestion. 2005;72:164–80.PubMedCrossRefGoogle Scholar
  51. 51.
    Ito M, Tanaka S, Takata S, Oka S, Imagawa S, Ueda H, et al. Morphological changes in human gastric tumours after eradication therapy of Helicobacter pylori in a short-term follow-up. Aliment Pharmacol Ther. 2005;21:559–66.PubMedCrossRefGoogle Scholar
  52. 52.
    Ito M, Tanaka S, Maeda M, Takamura A, Tatsugami M, Wada Y, et al. Role of the gastrin-gastrin receptor system in the expansive growth of human gastric neoplasms. Digestion. 2008;78:163–70.PubMedCrossRefGoogle Scholar
  53. 53.
    Tsuji N, Ishiguro S, Matsumura M, Yoshisato K, Umehara Y, Kudo M. Clinico-pathological time trends for early gastric cancer and Helicobacter pylori infection. Stomach Intest. 2007;42:931–6 (in Japanese).Google Scholar
  54. 54.
    Yoshihara M, Hiyama T, Yoshida S, Ito M, Tanaka S, Watanabe Y, et al. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study. Scand J Gastroenterol. 2007;42:760–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Miyamoto M, Haruma K, Yoshihara M, Sumioka M, Nishisaka T, Tanaka S, et al. Five cases of nodular gastritis and gastric cancer: a possible association between nodular gastritis and gastric cancer. Dig Liver Dis. 2002;34:819–20.PubMedCrossRefGoogle Scholar
  56. 56.
    Kamada T, Miyamoto M, Ito M, Sugiu K, Kusunoki H, Hata J, et al. Nodular gastritis is a risk factor for diffuse-type of gastric carcinoma in Japanese young patients. Gastroenterology. 2004;126:A456.Google Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • Masanori Ito
    • 1
  • Shunsuke Takata
    • 1
  • Masana Tatsugami
    • 1
  • Yoshihiro Wada
    • 1
  • Shinobu Imagawa
    • 1
  • Yoshiaki Matsumoto
    • 1
  • Akemi Takamura
    • 1
  • Shosuke Kitamura
    • 1
  • Taiji Matsuo
    • 1
  • Shinji Tanaka
    • 2
  • Ken Haruma
    • 3
  • Kazuaki Chayama
    • 1
  1. 1.Department of Medicine and Molecular ScienceHiroshima UniversityHiroshimaJapan
  2. 2.Department of EndoscopyHiroshima University HospitalHiroshimaJapan
  3. 3.Gastroenterology Unit, Department of Internal MedicineKawasaki Medical SchoolKurashikiJapan

Personalised recommendations